Secondary navigation: People section
1 / 2
Alternative e-mail:- email@example.com
Home Telephone 01279 657149
Mobile Phone 07710307505
Dr John Purves is a life science consultant having recently retired from the European Medicines Agency (EMA) where he worked for 14 years, as head of sector for the quality of medicines, including classic biological and biotechnology products. He has been involved in the development of legislation, guidelines and of the review procedures for dossiers submitted in support of applications for Marketing Authorisations in many areas dealing with such products, including recombinant-DNA, biosimilar, influenza and advanced therapy products.
Prior to joining the EMA, Dr Purves was manager of the biotechnology and biological unit, for 21 years, at the UK Medicines Control Agency, now the Medicines and Healthcare products Regulatory Agency. At the UK agency, he was involved in the drafting of some legislation, and of a number of supportive European Union guidelines, dealing with the manufacture and control of recombinant-DNA products and products derived from human blood and plasma. Dr Purves also oversaw efforts to minimise the risk of the transmission of spongiform encephalopathies to humans through medicinal products.
Dr Purves graduated in pharmacy from the Heriot Watt University in Edinburgh in 1968 and received his doctorate in pharmaceutical microbiology from the University of Strathclyde in 1973. Following university, he worked in research and development at Smith and Nephew Ltd in the UK.
Tait, J, Bruce, A, Mittra, J, Purves, J, Scannell, J (2014) ‘Independent review on anti-microbial resistance - regulation/innovation interactions and the development of antimicrobial drugs and diagnostics for human and animal diseases: Main Report’, Report to ESRC for the O’Neill Commission on Antimicrobial Resistance
Purves, J (2014) ‘Independent review on anti-microbial resistance - regulation/innovation interactions and the development of antimicrobial drugs and diagnostics for human and animal diseases: Supplementary Report 1 - An evaluation of drug and IVD regulation’, Report to ESRC for the O’Neill Commission on Antimicrobial Resistance